IDH-mutant glioma
Studies
Trials grouped by drug. Open a study for its arms and the response, survival, and safety figures a source reports.
33 studies across 15 of 15 drugs. 33 studies are in the file.
ASTX727 (decitabine/cedazuridine)1 study
- NCT03922555NCT03922555Phase 1Recruitingn 18
HMPL-306 (ranosidenib)2 studies
- NCT07912398NCT07912398Phase 3Not yet recruitingn 210
- NCT07025018NCT07025018Phase 1Recruitingn 52
IDH1-VAC (IDH1 R132H Peptide Vaccine)3 studies
Ivosidenib1 study
- Ivosidenib Phase 1 (glioma)NCT02073994Phase 1Completedn 174
Niraparib1 study
- NCT05406700NCT05406700Phase 1Active, not recruitingn 16
Nivolumab1 study
- NCT03718767NCT03718767Phase 2Active, not recruitingn 62
Olaparib3 studies
- OLAGLINCT03561870Phase 2Completedn 35
- SOLID (olaparib + durvalumab)NCT03991832Phase 2Active, not recruitingn 58
- NCT05188508NCT05188508Phase 2Recruitingn 57
Olutasidenib2 studies
- Olutasidenib Phase 1/2 (glioma cohort)NCT03684811Phase 1/2Completedn 93
- NCT06161974NCT06161974Phase 2Recruitingn 60
Pamiparib + Temozolomide1 study
- PNOC017NCT03749187Phase 1Active, not recruitingn 78
RT With Or Without Temozolomide (E3F05)1 study
- NCT00978458NCT00978458Phase 3Active, not recruitingn 540
Safusidenib (AB-218, DS-1001)5 studies
- J201 Phase 2NCT04458272Phase 2Active, not recruitingn 25
- SIGMANCT05303519Phase 3Recruitingn 365
- G307NCT07712757Phase 3Not yet recruitingn 140
- G209NCT07703436Phase 2Recruitingn 40
- SAFU-G3NCT07832123Phase 2Not yet recruitingn 20
Temozolomide Vs PCV With RT (CODEL)1 study
- NCT00887146NCT00887146Phase 3Active, not recruitingn 305
Tretinoin (ATRA) + Retifanlimab1 study
- NCT05345002NCT05345002Phase 2Recruitingn 55
Tuvusertib1 study
- TUVASTRATNCT07417761Phase 2Recruitingn 56
Vorasidenib9 studies
- INDIGONCT04164901Phase 3Active, not recruitingn 331
- Vorasidenib Phase 1Registry id n/rPhase n/rStatus n/rn n/r
- VORTEX (Alliance A072301)NCT07215910Phase 3Recruitingn 408
- VIGORNCT06809322Phase 3Recruitingn 468
- NCT06780930NCT06780930Phase 3Active, not recruitingn 57
- NCT06478212NCT06478212Phase 1/2Active, not recruitingn 51
- NCT05484622NCT05484622Phase 1Active, not recruitingn 60
- ViCToRyNCT05609994Phase 1Recruitingn 48
- VALIENTNCT07629089Phase 1Not yet recruitingn 36